XXXX Expression in Malignant Mixed M  llerian Tumors: A Potentially Targetable Biopredictor.

@entity3038 @entity1204 @entity7704 @entity5 @entity23376
UNASSIGNED: Malignant mixed @entity5 (MMMTs) are aggressive @entity5 with a high recurrence rate and poor prognosis. Despite advances in adjuvant therapies in recent years, the prognosis of these @entity5 has not improved. @entity7704 ( @entity7704 ) is produced by a variety of @entity5 and acts as a growth factor in an autocrine/paracrine manner. Its function requires the presence of its receptors to exert its effects on neoplastic cells. In this study, we evaluated the expression of @entity23376 ( @entity23376 ) in a group of MMMTs. Thirty-one examples of MMMTs from endometrium, ovary, uterine tube, and pelvic peritoneum were retrieved from the files of Department of Pathology at the University of Miami, Jackson Memorial Hospital. Immunohistochemistry for @entity23376 was performed on paraffin sections and the staining results were evaluated separately in both epithelial and mesenchymal components of each @entity5 . The presence of pituitary type @entity23376 mRNA and that of its biologically active splice variant were also evaluated by RT-PCR in 6 of the @entity5 . Positive immunohistochemical reaction for @entity23376 was detected in 30 @entity5 (96%). The epithelial and @entity3038 were positive in 30 (96%), whereas one @entity1204 was negative in both components. The mRNA for @entity23376 and its splice variant was found in all 6 tested @entity5 . This study shows that @entity23376 is expressed by the majority of MMMTs in both epithelial and mesenchymal components. This finding could potentially serve as a basis for therapeutic approaches using synthetic peptide antagonists of @entity23376 that have shown significant efficacy with minimal side effects in experimental models.
